This clinical data evaluates the effectiveness and safety of IBgard® for the management of IBS.
To learn more about the effectiveness and safety of IBgard® for the dietary management of IBS, view the abstract or download a copy of “A Novel Delivery System of Peppermint Oil Is an Effective Therapy for Irritable Bowel Syndrome,” published in Digestive Diseases and Sciences, a peer reviewed journal.
IBgard® Clinical Data
IBgard®, a novel, small-intestine-targeted delivery system of peppermint oil, results in significant improvement in severe and unbearable IBS symptom intensity.
Approximately 25% of patients with irritable bowel syndrome (IBS) describe their symptoms as severe. Multiple items (mean=7) have been identified as contributing to IBS severity. The level of severity seems related to the number and intensity of these contributing factors. High severity is reflected by higher intensity and higher frequency of individual symptoms.
IBgard®, a novel, targeted-delivery system of peppermint oil, results in significant improvement in the Total IBS Symptom Score and individual IBS symptoms.
Peppermint oil (PO) has been shown to significantly reduce global symptoms as well as the abdominal pain of irritable bowel syndrome (IBS). 1 It is approved by the European Medicines Agency (EMEA) and used as a first line IBS therapy outside the United States.
24 hour results from the IBSREST trial: a U.S.-based, randomized, placebo-controlled, multi-centered trial to evaluate a novel peppermint oil delivery system.
Irritable bowel syndrome (IBS) is a chronic disorder with periodic exacerbations of symptoms that can be severe. The incidence of the three major forms of IBS has been reported as IBS-M (61.0%), IBS-D (29.3%), and IBS-C (9.7%).
Peppermint Oil Clinical Data
Targeted delivery of peppermint oil to the small intestine provides significant improvement in the syndrome of symptoms associated with Irritable Bowel Syndrome.
Irritable bowel syndrome (IBS) is a chronic disorder with periodic exacerbations of eight major symptoms, including abdominal pain or discomfort, abdominal bloating, constipation, diarrhea, incomplete evacuation, pain at evacuation, passage of gas or mucus, and urgency of bowel movement.
The IBgard® Difference